Emphysema Market: Global Industry Analysis and Forecast (2024-2030)

  • Emphysema Market size was valued at USD 4.71 Bn. in 2023 and the total Emphysema Market size is expected to grow at a CAGR of 4.28% from 2024 to 2030, reaching nearly USD 6.32 Bn. by 2030.

  • Format : PDF | Report ID : SMR_2066

Emphysema Market Overview

Emphysema is a lung illness within the lower respiratory system where the alveoli (lung air sacs) are impaired leading to less oxygen being moved into the bloodstream. Tobacco smoking, high levels of air pollution and exposure to chemical fumes and dust have been identified as the main drivers of the emphysema market as a result of increasing prevalence of respiratory infections. In addition, the market is also growing because of the rising incidences of genetic disorders caused by inherited gene mutations and DNA abnormalities. On another note, this is because there has been more over the years use of effective medications for example bronchodilators, corticosteroids or anti-inflammatory drugs in treating this condition.

 

Lung scintigraphy, help to detect the most severely affected parts of the lungs, is also acting as a significant growth-inducing factor, utilizing radioisotopes to visualize lung ventilation and perfusion. Targeted biologics such as monoclonal antibodies for targeting eosinophilic inflammation moreover are anticipated to encourage widespread adoption due to their efficacy in reducing disease exacerbation.

Emphysema Market

 

To get more Insights: Request Free Sample Report

 

Emphysema Market Dynamics

Drivers: Growing Aging Population

The elderly are greatly responsible for the large emphysema drug market. Emphysema is more common in old people due to continuous inhalation of dangerous substances like first and secondhand smoking. Within time, the need for such drugs in addition to treatment approaches will be on the increase, as global population gradually ages. This is very apparent especially in developed countries where people live long.

 

Advancements in Drug Delivery Systems

There have been significant advances in the pharmaceutical field with regards to improved drug delivery systems that target emphysema. For instance, devices like inhalers, nebulizers, among others have been developed so that people can receive different types of medicines for instance into the lung more easily. It is also true that such innovation promotes better adherence on the part of clients as they allow them to give themselves treatment without any help.

 

Restrain/Challenges

Increasing Cost of Treatment Therapeutics

Factors that contribute to the increase in the cost of treating emphysema include advanced therapeutic options, such as medications, pulmonary rehabilitation programs, and surgical interventions like lung volume reduction surgery or lung transplantation. In addition, treatment expenses are further increased by the management of co-morbidities that are associated with Emphysema.

 

Emphysema Market Segment Analysis:

Based on Type Emphysema Market is divided into Centriacinar, Panacinar, Paraseptal, and Others. The centriacinar segment dominated the global emphysema treatment market share in 2023 and is expected to register the fastest growth in the forecast period, owing to the fact that centriacinar is one of the most prevalent forms of emphysema, particularly among smokers, who represent a significant portion of the population affected by this condition. Centriacinar is characterized by damage primarily to the central or proximal portions of the acinus within the lungs. While Panacinar and Paraseptal are used in serious condition to give instant effect on patients.

Emphysema Market1

Emphysema Market Regional Insights:

Region Wise North America Dominated the Emphysema Market. In the United States and Canada, emphysema is a significant public health concern due to high smoking rates and environmental factors. Advanced healthcare infrastructure and extensive research contribute to the availability of a wide range of treatment options, including pharmaceuticals, pulmonary rehabilitation programs, and surgical interventions. The market is characterized by the presence of key players offering innovative therapies and a strong emphasis on personalized medicine approaches. Moreover, the emphysema market is influenced by regional healthcare infrastructure, socio-economic factors, and environmental conditions, shaping the distribution and adoption of therapies worldwide.

 

North America Emphysema Market attributed to advanced medical facilities available in the region and high level of healthcare spending, which facilitates the adoption of novel treatments for emphysema. In addition, extensive R and D activities, along with a supportive regulatory environment, have propelled the development and commercialization of emphysema treatment products in North America.

Emphysema Market2

Emphysema Market Competitive Landscape

  • In December 2023, AstraZeneca India, a science-led biopharmaceutical company, announced that it has received Central Drugs Standard Control Organization (CDSCO) approval to market its inhalation aerosol, a triple combination of budesonide (160 mcg), glycopyrrolate (9 mcg), and formoterol fumarate (4.8 mcg) for maintenance treatment of COPD.
  • In August 2023, clinical research was conducted on the biologic medication Dupixent which was developed by Regeneron and Sanofi in a collaboration. The trial showcased positive results indicating that it could be used to treat COPD exacerbations and improve lung function effectively. Dupixent is an approved drug and is used for treating patients with eczema or allergic asthma.
  • In March 2022, the department of veteran’s affairs launched its novel HER in Columbus, Ohio at the VA Central Ohio healthcare system

 

Emphysema Market Scope

Emphysema Market

Market Size in 2023

USD 4.71Bn.

Market Size in 2030

USD 6.32 Bn.

CAGR (2024-2030)

4.28 %

Historic Data

2018-2022

Base Year

2023

Forecast Period

2024-2030

   Segments

By Type

  • Centriacinar
  • Panacinar
  • Paraseptal
  • Others

By Treatment

  • Medication
  • Therapy
  • Surgery
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Scope

North America- United States, Canada, and Mexico

Europe – United Kingdom, France, Germany, Italy, Spain, Sweden, Russia, and Rest of Europe

Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC

Middle East and Africa - South Africa, GCC, Egypt, Rest of the Middle East and Africa

South America – Brazil, Argentina, Rest of South America

 

Emphysema Market Key Players

  • GlaxoSmithKline plc. (UK)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Novartis AG (Switzerland)
  • Eli Lilly and Company. (U.S.)
  • AstraZeneca (UK)
  • Pfizer Inc. (U.S.)
  • Takeda Pharmaceutical Company Limited. (Japan)
  • Bristol-Myers Squibb Company (U.S.)
  • Sanofi (France)
  • Bayer AG (Germany)
  • AbbVie Inc. (U.S.)
  • Allergan (Ireland)
  • Precigen (U.S.)
  • Pulmonx Corporation (U.S.)
  • Halozyme, Inc. (U.S.)
  • Mmariposa Health (U.S.)
  • Kamada Pharmaceuticals (Israel)
  • Olympus Corporation (Japan)
  • Spiration, Inc.(U.S.)
  • Lifetech Scientific (China)
  • XX Inc


Frequently Asked Questions

Increasing Prevalence of Emphysema Drives the Global Market, Ongoing Trails and research developments are the growth drivers for the Emphysema Market.

1.    Emphysema Market: Research Methodology 
2.    Emphysema Market: Executive Summary
3.    Emphysema Market: Competitive Landscape
4.    Potential Areas for Investment

4.1. Stellar Competition Matrix
4.2. Competitive Landscape
4.3. Key Players Benchmarking
4.4. Market Structure
4.4.1.    Market Leaders 
4.4.2.    Market Followers
4.4.3.    Emerging Players

4.5. Consolidation of the Market
5.    Emphysema Market Import Export Landscape
5.1. Import Trends
5.2. Export Trends
5.3. Regulatory Compliance
5.4. Major Export Destinations
5.5. Import-Export Disparities
6.    Emphysema Market: Dynamics
6.1. Market Trends by Region
6.1.1.    North America
6.1.2.    Europe
6.1.3.    Asia Pacific
6.1.4.    Middle East and Africa
6.1.5.    South America

6.2. Market Drivers by Region
6.2.1.    North America
6.2.2.    Europe
6.2.3.    Asia Pacific
6.2.4.    Middle East and Africa
6.2.5.    South America

6.3. Market Restraints
6.4. Market Opportunities
6.5. Market Challenges
6.6. PORTER’s Five Forces Analysis
6.7. PESTLE Analysis
6.8. Strategies for New Entrants to Penetrate the Market
6.9. Regulatory Landscape by Region
6.9.1.    North America
6.9.2.    Europe
6.9.3.    Asia Pacific
6.9.4.    Middle East and Africa
6.9.5.    South America

7.    Emphysema Market Size and Forecast by Segments (by Value Units)
7.1. Emphysema Market Size and Forecast, by Type (2023-2030)
7.1.1.    Centriacinar
7.1.2.    Panacinar
7.1.3.    Paraseptal
7.1.4.    Others

7.2. Emphysema Market Size and Forecast, by Treatment (2023-2030)
7.2.1.    Medication
7.2.2.    Therapy
7.2.3.    Surgery
7.2.4.    Others 

7.3. Emphysema Market Size and Forecast, by End User (2023-2030)
7.3.1.    Hospitals and Clinics
7.3.2.    Research and Academic Institutes
7.3.3.    Others 

7.4. Emphysema Market Size and Forecast, by Region (2023-2030)
7.4.1.    North America
7.4.2.    Europe
7.4.3.    Asia Pacific
7.4.4.    Middle East and Africa
7.4.5.    South America

8.    North America Emphysema Market Size and Forecast (by Value Units)
8.1. North America Emphysema Market Size and Forecast, by Type (2023-2030)
8.1.1.    Centriacinar
8.1.2.    Panacinar
8.1.3.    Paraseptal
8.1.4.    Others

8.2. Emphysema Market Size and Forecast, by Treatment (2023-2030)
8.2.1.    Medication
8.2.2.    Therapy
8.2.3.    Surgery
8.2.4.    Others 

8.3. Emphysema Market Size and Forecast, by Distribution Channel (2023-2030)
8.3.1.    Hospital Pharmacy
8.3.2.    Online Pharmacy
8.3.3.    Retail Pharmacy 

8.4. North America Emphysema Market Size and Forecast, by Country (2023-2030)
8.4.1.    United States
8.4.2.    Canada
8.4.3.    Mexico

9.    Europe Emphysema Market Size and Forecast (by Value Units)
9.1. Europe Emphysema Market Size and Forecast, by Type (2023-2030)
9.1.1.    Centriacinar
9.1.2.    Panacinar
9.1.3.    Paraseptal
9.1.4.    Others 

9.2. Emphysema Market Size and Forecast, by Treatment (2023-2030)
9.2.1.    Medication
9.2.2.    Therapy
9.2.3.    Surgery
9.2.4.    Others 

9.3. Emphysema Market Size and Forecast, by Distribution Channel (2023-2030)
9.3.1.    Hospital Pharmacy
9.3.2.    Online Pharmacy
9.3.3.    Retail Pharmacy  

9.4. Europe Emphysema Market Size and Forecast, by Country (2023-2030)
9.4.1.    UK
9.4.2.    France
9.4.3.    Germany
9.4.4.    Italy
9.4.5.    Spain
9.4.6.    Sweden
9.4.7.    Russia 
9.4.8.    Rest of Europe

10.    Asia Pacific Emphysema Market Size and Forecast (by Value Units)
10.1. Asia Pacific Emphysema Market Size and Forecast, by Type (2023-2030)
10.1.1.    Centriacinar
10.1.2.    Panacinar
10.1.3.    Paraseptal
10.1.4.    Others

10.2. Emphysema Market Size and Forecast, by Treatment (2023-2030)
10.2.1.    Medication
10.2.2.    Therapy
10.2.3.    Surgery
10.2.4.    Others 

10.3. Emphysema Market Size and Forecast, by Distribution Channel (2023-2030)
10.3.1.    Hospital Pharmacy
10.3.2.    Online Pharmacy
10.3.3.    Retail Pharmacy 

10.4. Asia Pacific Emphysema Market Size and Forecast, by Country (2023-2030)
10.4.1.    China
10.4.2.    S Korea
10.4.3.    Japan
10.4.4.    India
10.4.5.    Australia
10.4.6.    Indonesia 
10.4.7.    Malaysia
10.4.8.    Vietnam
10.4.9.    Taiwan
10.4.10.    Bangladesh
10.4.11.    Pakistan
10.4.12.    Rest of Asia Pacific

11.    Middle East and Africa Emphysema Market Size and Forecast (by Value Units)
11.1. Middle East and Africa Emphysema Market Size and Forecast, by Type (2023-2030)
11.1.1.    Centriacinar
11.1.2.    Panacinar
11.1.3.    Paraseptal
11.1.4.    Others

11.2. Middle East and Africa Market Size and Forecast, by Treatment (2023-2030)
11.2.1.    Medication
11.2.2.    Therapy
11.2.3.    Surgery
11.2.4.    Others 

11.3. Emphysema Market Size and Forecast, by Distribution Channel (2023-2030)
11.3.1.    Hospital Pharmacy
11.3.2.    Online Pharmacy
11.3.3.    Retail Pharmacy

11.4. Middle East and Africa Emphysema Market Size and Forecast, by Country (2023-2030)
11.4.1.    South Africa
11.4.2.    GCC
11.4.3.    Egypt
11.4.4.    Nigeria
11.4.5.    Rest of ME&A

12.    South America Emphysema Market Size and Forecast (by Value Units)
12.1. South America Emphysema Market Size and Forecast, by Type (2023-2030)
12.1.1.    Centriacinar
12.1.2.    Panacinar
12.1.3.    Paraseptal
12.1.4.    Others

12.2. South America Market Size and Forecast, by Treatment (2023-2030)
12.2.1.    Medication
12.2.2.    Therapy
12.2.3.    Surgery
12.2.4.    Others

12.3. Emphysema Market Size and Forecast, by Distribution Channel (2023-2030)
12.3.1.    Hospital Pharmacy
12.3.2.    Online Pharmacy
12.3.3.    Retail Pharmacy 

12.4. South America Emphysema Market Size and Forecast, by Country (2023-2030)
12.4.1.    Brazil
12.4.2.    Argentina
12.4.3.    Rest of South America

13.    Company Profile: Key players
13.1.1.    GlaxoSmithKline plc. (UK)
13.1.1.1.    Company Overview
13.1.1.2.    Financial Overview
13.1.1.3.    Business Portfolio
13.1.1.4.    SWOT Analysis
13.1.1.5.    Business Strategy 
13.1.1.6.    Recent Developments

13.2. F. Hoffmann-La Roche Ltd (Switzerland)
13.3. Novartis AG (Switzerland)
13.4. Eli Lilly and Company. (U.S.)
13.5. AstraZeneca (UK)
13.6. Pfizer Inc. (U.S.)
13.7. Takeda Pharmaceutical Company Limited. (Japan)
13.8. Bristol-Myers Squibb Company (U.S.)
13.9. Sanofi (France)
13.10. Bayer AG (Germany)
13.11. AbbVie Inc. (U.S.)
13.12. Allergan (Ireland)
13.13. Precigen (U.S.)
13.14. Pulmonx Corporation (U.S.)
13.15. Halozyme, Inc. (U.S.)
13.16. Mmariposa Health (U.S.)
13.17. Kamada Pharmaceuticals (Israel)
13.18. Olympus Corporation (Japan)
13.19. Spiration, Inc. (U.S.)
13.20. Lifetech Scientific (China)
13.21. XX Inc  
14.    Key Findings
15.    Industry Recommendation

Enquiry Before Buy


Request Sample PDF